Jump to:Page Content
Stand out from the crowd! Advertise in Trial to reach a national audience of major decision-makers who are looking for products and services to improve their legal practices.
Alyssa E. Lambert
The Supreme Court agreed to consider whether federal law preempts state products liability claims that allege design defects against generic drug manufacturers in a case that could further impede plaintiffs’ ability to bring similar lawsuits and hold these companies accountable. The First Circuit’s ruling in Mutual Pharmaceutical Co., Inc. v. Bartlett is the only appellate decision to tackle the design defect issue since the Court preempted failure-to-warn claims in Pliva, Inc. v. Mensing, so plaintiff attorneys will be closely watching the outcome.